SCHEMBL5134640

SCHEMBL5134640

CCCCn1c(CN(Cc2cccc(C)c2)Cc2ccc3c(c2)OCO3)cnc1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.56
SMN1; SMN2 Q16637 4/20 0.43
TDP1 Q9NUW8 1/20 0.43
LMNA P02545 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
F2R P25116 2/20 0.41
TSHR P16473 4/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MAPT P10636 2/20 0.38
CYP1A2 P05177 3/20 0.38
CYP3A4 P08684 3/20 0.38
CYP2D6 P10635 3/20 0.38
MAPK1 P28482 3/20 0.38
CYP2C19 P33261 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134857 0.95 C5AR1 (0.60) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL647999 0.95 C5AR1 (0.62) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL5136776 0.94 C5AR1 (0.57) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL5073883 0.93 C5AR1 (0.58) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL5135773 0.92 C5AR1 (0.48) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL5135566 0.92 C5AR1 (0.57) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL5136907 0.91 C5AR1 (0.55) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL5136811 0.91 C5AR1 (0.55) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL5134878 0.91 C5AR1 (0.55) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL5135640 0.91 C5AR1 (0.55) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed